Skip to Content

Join the 'Elotuzumab' group to help and get support from people like you.

Elotuzumab News

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to ...

Empliciti Approved for Multiple Myeloma

Posted 1 Dec 2015 by Drugs.com

MONDAY, Nov. 30, 2015 – Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who have already been given one-to-three prior therapies for the disease. Multiple myeloma is a type of cancer that affects germ-fighting white blood cells produced in ...

FDA Approves Empliciti (elotuzumab) for Multiple Myeloma

Posted 1 Dec 2015 by Drugs.com

November 30, 2015 – Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white blood cell) found in the bone marrow. These cancerous ...

Ask a Question

Further Information

Related Condition Support Groups

Multiple Myeloma

Related Drug Support Groups

Empliciti

Elotuzumab Patient Information at Drugs.com